<br>        Inclusion Criteria:<br><br>          -  GFR=25ml/min/1.73m2 calculated by the MDRD equation<br><br>          -  Urinary total protein: creatinine ratios >200mg/mmol derived from the average of 2<br>             first morning voids taken during screening period<br><br>          -  Biopsy confirmed as idiopathic FSGS by a central reviewer<br><br>          -  Treatment resistance. NOTE:Patients to have received minimum 6 week course of<br>             steroids or immunosuppressant<br><br>          -  If receiving treatment with an ACEi and/or ARB dose to be stable for a minimum of 4<br>             weeks prior to randomization<br><br>          -  Influenza vaccine (according to season)<br><br>          -  Negative screening per American Cancer Society (ACS) 2003 guidelines,     as<br>             appropriate to patient demographics and clinical status<br><br>        Exclusion Criteria:<br><br>          -  Secondary FSGS<br><br>          -  steroid resistant patients who are unable to reduce their steroid dose to <10mg/day<br>             of prednisolone or equivalent 4 weeks prior to study dosing day<br><br>          -  Positive serology for serious infections (including but not limited to infection with<br>             Hep B or C, HIV)<br><br>          -  Concomitant illnesses:Diabetes Type I; Cardiac or Hepatic disease, HIV; Cancer,<br>             precancerous state (eg familial adenomatous polyposis; Any condition requiring<br>             treatment with other immunosuppressant drugs    within 4 weeks prior to dosing day or<br>             during the course of the study<br><br>          -  Pre-existing oral-pharyngeal disease (dental carries and other minor dental disease<br>             are acceptable)<br><br>          -  Haemoglobin level of <9.0g/dL prior to dosing<br><br>          -  Treatment with coumadin, anti-vitamin K analogues or low molecular weight heparins.<br>             Patients must have stopped treatment a minimum of four weeks prior to receiving study<br>             medication.<br><br>          -  Patients requiring ongoing treatment with non-steroidal anti-inflammatory drugs<br>             (NSAIDs).  Patients must have stopped treatment a minimum of four weeks prior to<br>             receiving study medication.<br><br>          -  Patients who have had surgery/fracture within 3 months prior to dosing day<br><br>          -  History of cancer unresolved within 5 years prior to screening or a known<br>             precancerous state; or any form of skin cancer either current or past history<br><br>          -  Women who are pregnant, lactating or who plan to become pregnant within 4 months of<br>             infusion<br><br>          -  Women of childbearing potential unless taking medically acceptable contraceptive<br><br>          -  Men with female partners of childbearing potential unless they are taking medically<br>             acceptable contraceptive precautions<br><br>          -  Use of any investigation drug administered as part of a clinical trial within 4 weeks<br>             prior to commencing screening<br><br>          -  Other clinically significant, uncontrolled medical condition that in the<br>             investigator's opinion may interfere with the assessment or follow-up<br><br>          -  Active ethanol or drug abuse, excluding tobacco use<br><br>          -  Electrocardiogram (ECG) abnormalities considered to be clinically significant at<br>             screening<br><br>          -  Unable to comply with the requirements of the study<br><br>          -  Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or use<br>             of anticoagulation therapy (including anti-platelet agents). Patients with a history<br>             of deep venous thrombosis may participate if successfully treated, completely<br>             resolved, and no treatment has been given for >4 months.<br>